​

Ascendis Pharma (ASND) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

ASND Stock Forecast

Ascendis Pharma (ASND) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $287.17, with a high of $342.00 and a low of $250.00. This represents a 19.40% increase from the last price of $240.52.

$100 $150 $200 $250 $300 $350 High: $342 Avg: $287.17 Low: $250 Last Closed Price: $240.52

ASND Stock Rating

Ascendis Pharma stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (91.67%), 2 Hold (8.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 24 0 2 22 Strong Sell Sell Hold Buy Strong Buy

ASND Price Target Upside V Benchmarks

TypeNameUpside
StockAscendis Pharma19.40%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts101417
Avg Price Target$284.90$292.36$284.29
Last Closing Price$240.52$240.52$240.52
Upside/Downside18.45%21.55%18.20%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26313---16
Feb, 26313---16
Jan, 26213---15
Dec, 25213---15
Nov, 25312---15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 05, 2026Jefferies$262.00$237.3510.39%8.93%
Mar 04, 2026Alex ThompsonStifel Nicolaus$332.00$241.3837.54%38.03%
Mar 02, 2026Kalpit PatelWolfe Research$260.00$231.4612.33%8.10%
Mar 02, 2026Li WatsekCantor Fitzgerald$300.00$231.4329.63%24.73%
Mar 02, 2026Josh SchimmerEvercore ISI$324.00$234.0738.42%34.71%
Mar 02, 2026Paul ChoiGoldman Sachs$255.00$233.509.21%6.02%
Feb 12, 2026Wedbush$273.00$218.3925.01%13.50%
Feb 12, 2026Oppenheimer$262.00$217.9320.22%8.93%
Feb 12, 2026Alex ThompsonStifel Nicolaus$325.00$218.0449.06%35.12%
Feb 12, 2026Maxwell SkorMorgan Stanley$256.00$221.4915.58%6.44%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 05, 2026Bank of America SecuritiesBuyBuyhold
Mar 02, 2026RBC CapitalOutperformOutperformhold
Mar 02, 2026Wolfe ResearchOutperformOutperformhold
Mar 02, 2026Cantor FitzgeraldOverweightOverweighthold
Mar 02, 2026Evercore ISIOutperformOutperformhold
Mar 02, 2026Goldman SachsBuyBuyhold
Feb 12, 2026WedbushOutperformOutperformhold
Feb 12, 2026OppenheimerOutperformOutperformhold
Feb 12, 2026Morgan StanleyOverweightOverweighthold
Jan 27, 2026BarclaysOverweightinitialise

Financial Forecast

EPS Forecast

$-15 $-6 $3 $12 $21 $30 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.00$-10.40$-8.55-----
Avg Forecast$-7.41$-9.55$-8.86$-6.98$-3.90$1.06$10.04$13.91
High Forecast$-6.04$-7.77$-7.55$-5.72$-1.46$5.22$26.67$21.09
Low Forecast$-10.50$-14.59$-10.95$-7.73$-6.36$-0.88$3.69$10.79
Surprise %-5.53%8.90%-3.50%-----

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$7.78M$51.17M$266.72M-----
Avg Forecast$6.60M$45.90M$224.61M$300.07M$530.08M$1.00B$1.73B$2.32B
High Forecast$8.71M$64.54M$279.10M$365.49M$749.98M$1.01B$2.41B$3.24B
Low Forecast$5.66M$39.31M$194.11M$258.44M$448.72M$996.14M$1.43B$1.92B
Surprise %17.89%11.49%18.75%-----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-383.58M$-583.19M$-481.45M-----
Avg Forecast$-417.32M$-537.67M$-437.49M$-381.83M$-196.74M$137.26M$538.04M$782.81M
High Forecast$-340.10M$-437.37M$-425.03M$-322.10M$-82.43M$293.94M$1.50B$1.19B
Low Forecast$-590.82M$-821.49M$-616.22M$-435.36M$-357.87M$-49.59M$207.64M$607.46M
Surprise %-8.08%8.47%10.05%-----

ASND Forecast FAQ

Is Ascendis Pharma stock a buy?

Ascendis Pharma stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Ascendis Pharma is a favorable investment for most analysts.

What is Ascendis Pharma's price target?

Ascendis Pharma's price target, set by 24 Wall Street analysts, averages $287.17 over the next 12 months. The price target range spans from $250 at the low end to $342 at the high end, suggesting a potential 19.40% change from the previous closing price of $240.52.

How does Ascendis Pharma stock forecast compare to its benchmarks?

Ascendis Pharma's stock forecast shows a 19.40% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Ascendis Pharma over the past three months?

  • March 2026: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 18.75% Strong Buy, 81.25% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 13.33% Strong Buy, 86.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Ascendis Pharma’s EPS forecast?

Ascendis Pharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-6.98, marking a -18.36% decrease from the reported $-8.55 in 2023. Estimates for the following years are $-3.9 in 2025, $1.06 in 2026, $10.04 in 2027, and $13.91 in 2028.

What is Ascendis Pharma’s revenue forecast?

Ascendis Pharma's average annual revenue forecast for its fiscal year ending in December 2024 is $300.07M, reflecting a 12.50% increase from the reported $266.72M in 2023. The forecast for 2025 is $530.08M, followed by $1B for 2026, $1.73B for 2027, and $2.32B for 2028.

What is Ascendis Pharma’s net income forecast?

Ascendis Pharma's net income forecast for the fiscal year ending in December 2024 stands at $-382M, representing a -20.69% decrease from the reported $-481M in 2023. Projections indicate $-197M in 2025, $137.26M in 2026, $538.04M in 2027, and $782.81M in 2028.